Advertisement

International Journal of Hematology

, Volume 75, Issue 2, pp 129–140 | Cite as

Immunosuppressive Treatment of Acquired Aplastic Anemia and Immune-Mediated Bone Marrow Failure Syndromes

Progress in Hematology

Abstract

Modern therapeutic strategies for the treatment of acquired aplastic anemia are based on the current understanding of its pathophysiology as well as empiric observations. Most cases of aplastic anemia appear to be the result of immune-mediated destruction of hematopoietic cells, which can be approached by stem cell transplantation in younger patients with appropriate histocompatible donors or by immunosuppression to reduce T-cell activity. Popular treatment regimens combine antithymocyte globulin with cyclosporine. Although a majority of patients respond with improved blood counts and achieve transfusion-independence, late clonal complications of myelodysplasia and cytogenetic abnormalities occur in a substantial minority of cases. Additionally, there is no clear algorithm for the treatment of refractory disease. Newer methods of treatment, including high-dose cyclophosphamide and the development of potentially tolerizing combinations of drugs, are under study. Effective therapies for aplastic anemia might also be applied to other T-cell mediated, organ-specific human diseases.

Key words

Autoimmunity Bone marrow Hematopoiesis Antithymocyte globulin Antilymphocyte globulin Cyclosporine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referencess

  1. 1.
    Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine.Semin Hematol. 2000;37:56–68.PubMedGoogle Scholar
  2. 2.
    Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience.Semin Hematol. 2000;37:69–80.PubMedGoogle Scholar
  3. 3.
    Marsh JCW. Results of immunosuppression in aplastic anaemia.Acta Haematol. 2000;103:26–32.PubMedGoogle Scholar
  4. 4.
    Kojima S, Nakao S, Tomonaga M, et al. Consensus conference on the treatment of aplastic anemia.Int J Hematol. 2000;72:118–123.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Ball SE. The modern management of severe aplastic anaemia.Br J Haematol. 2000;110:41–53.PubMedGoogle Scholar
  6. 6.
    Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia.N Engl J Med. 1997;336:1365–1372.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Sloand E, Maciejewski JP, Kim S, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo.Blood. 2000;95:2269–2274.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Mathé G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum.Br Med J. 1970;2:131–136.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Jeannet M, Speck B, Rubinstein A, Pelet B, Wyss M, Kummer H. Autologous marrow reconstitutions in severe aplastic anaemia after ALG pretreatment and HL-A semi-incompatible bone marrow cell transfusion.Acta Haematol. 1976;55:129–139.PubMedGoogle Scholar
  10. 10.
    Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions.Lancet. 1977;2:1145–1148.PubMedGoogle Scholar
  11. 11.
    Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation.Br Med J. 1981;282:860–863.Google Scholar
  12. 12.
    Camitta B, O’Reilly RJ, Sensenbrenner L, et al. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia.Blood. 1983;62:883–888.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia.N Engl J Med. 1983;308:113–118.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Young N, Griffith P, Brittain E, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases.Blood. 1988;72:1861–1869.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Leong KW, Teh A, Bosco JJ, Jayaranee S, Sadat U. Anti-lymphocyte globulin therapy in aplastic anaemia-a university hospital experi ence.Med J Malaysia. 1995;50:158–161.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model.Transplantation. 2001;71:460–468.PubMedGoogle Scholar
  17. 17.
    Genestier L, Fournel S, Flacher M, Assossou O, Revillard J-P, Bon nefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulin.Blood. 1998;91:2360–2368.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin.Transplantation. 1998;65:1481–1489.PubMedGoogle Scholar
  19. 19.
    Teramura M, Kobayashi S, Iwabe K, Yoshinaga K, Mizoguchi H. Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism.Br J Haematol. 1997;96:80–84.PubMedGoogle Scholar
  20. 20.
    Kook H, Risitano A, Zeng W, et al. Changes in T-cell receptor Vβ-repertoire in aplastic anemia. Effects of different immunosuppressive regimens.Exp Hematol. In press.Google Scholar
  21. 21.
    Myint AA, Malkovska V, Morgan S, Luckit J, Wonke B, Gordon-Smith EC. Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anemia.Br J Haematol. 1990;75:578–584.PubMedGoogle Scholar
  22. 22.
    Nimer SD, Golde DW, Kwan K, Lee K, Clark S, Champlin R. In vitro production of granulocyte-macrophage colony stimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin.Blood. 1991;78:163–168.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Abe T, Matsuoka H, Kojima S, et al. Correlation of response of aplastic anemia patients to antilymphocyte globulin with in vitro lymphocyte stimulatory effect: predictive value of in vitro test for clinical response.Blood. 1991;77:2225–2230.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Marsh JC. Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia.Semin Hematol. 2000;37:81–90.PubMedGoogle Scholar
  25. 25.
    Killick SB, Marsh JC, Gordon-Smith EC, Sorlin L, Gibson FM. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia.Br J Haematol. 2000;108:582–591.PubMedGoogle Scholar
  26. 26.
    Chen G, Kook H, Zeng W, Young NS, Maciejewski JP. Is there a direct effect of antithymocyte globulin on hematopoiesis?Exp Hematol. In press.Google Scholar
  27. 27.
    Bayever E, Champlin R, Ho W, et al. Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia.J Pediatr. 1984;105:920–925.PubMedGoogle Scholar
  28. 28.
    Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy.Ann Intern Med. 1997;126:107–115.PubMedGoogle Scholar
  29. 29.
    Osman I, Koc H, Ismet A, et al. Combined immunosuppressive therapy in aplastic anemia.Indian J Med Res. 1995;102:143–146.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Delgado-Lamas JL, Lopez-Karpovitch X, Marin-Lopez A, et al. Low doses of high-potency antithymocyte globulin (ATG) in severe aplastic anemia: experience with the Mexican ATG.Acta Haematol. 1989;81:70–74.PubMedGoogle Scholar
  31. 31.
    Bielory L, Wright R, Nienhuis AW, Young NS, Kaliner MA. Antithymocyte globulin hypersensitivity in bone marrow failure patients.JAMA. 1988;260:3164–3167.PubMedGoogle Scholar
  32. 32.
    Bielory L, Lawley T, Gascon P, Yancey K, Young N, Frank MM. Human serum sickness after equine antithymocyte globulin in patients with bone marrow failure.Medicine (Baltimore). 1988;67:40–57.Google Scholar
  33. 33.
    Shahidi NT, Wang WC, Shurin SB, Finlay JL, Sondel PM, Dinndorf PA. Treatment of acquired aplastic anemia with cyclosporine and androgens. In: Shahidi NT, ed.Aplastic Anemia and Other Bone Marrow Failure Syndromes. London: Springer-Verlag; 1990:155–165.Google Scholar
  34. 34.
    Hinterberger-Fischer M, Hocker P, Lechner K, Seewann H, Hinterberger W Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure.Eur J Haematol. 1989;43:136–142.PubMedGoogle Scholar
  35. 35.
    Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia.Br J Haematol. 1989;72:278–284.PubMedGoogle Scholar
  36. 36.
    Leeksma OC, Thomas LL, Van der Leslie J, Van Oers MH, von dem Borne AE, Goudsmit R. Effectiveness of low dose cyclosporine in acquired aplastic anaemia with severe neutropenia.Neth J Med. 1992;41:143–148.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia.Blood. 1992;79:2540–2546.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Raghavachar A, Kolbe K, Höffken K, et al. A randomized trial of standard immunosuppression versus cyclosporine and filgastrim in severe aplastic anemia [abstract].Blood 1997;90(suppl 1):439a.Google Scholar
  39. 39.
    Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party.Blood. 1999;93:2191–2195.PubMedGoogle Scholar
  40. 40.
    Zhang N, Shao Z. Efficacy of cyclosporin A in the treatment of aplastic anemia and its mechanism.Zhonghua Xue Ye Xue Za Zhi. 1998;19:218–220.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Varma SVN, Malhotra P, Singh S, Sharma DR. Cyclosporin A monotherapy in young Indian aplastic anaemia patients.J Indian Med Assoc. 1999;97:505–506.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Maschan A, Bogatcheva N, Kryjanovski O, et al. Results at a single centre of immunosuppression with cyclosporine A in 66 children with aplastic anaemia.Br J Haematol. 1999;106:967–970.PubMedGoogle Scholar
  43. 43.
    Kalechman Y, Sredni B, Caspi RR, Nussenblatt RB. Enhancing effect of cyclosporins A and G on bone marrow colony formation.Exp Hematol. 1990;18:1104–1107.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Tong J, Bacigalupo A, Piaggio G, et al. Severe aplastic anemia (SAA): response to cyclosporin A (CyA) in vivo and in vitro.Eur J Haematol. 1991;46:212–216.PubMedGoogle Scholar
  45. 45.
    Hirao A, Kawano Y, Takaue Y. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis.Blood. 1993;81:1179–1183.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia.Blood. 1994;84:4257–4261.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Hirose YMY, Ebata K, Okada J, et al. T-cell type acute lymphoblastic leukemia following cyclosporin a therapy for aplastic anemia.Int J Hematol. 2000;73:226–229.Google Scholar
  48. 48.
    Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylpred-nisolone with or without cyclosporine. The German Aplastic Anemia Study Group.N Engl J Med. 1991;324:1297–1304.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immuno-suppression with antithymocyte globulin and cyclosporine as treat ment for severe acquired aplastic anemia.Blood. 1995;85:3058–3065.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Rosenfeld SJ, Nunez O, Follman D, Young NS. Long-term outcome in severe aplastic anemia is predicted by blood counts after treatment with intensive immunosuppression [abstract].Blood. 2001;98(suppl 1):749a.Google Scholar
  51. 51.
    Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party.Blood. 1995;85:1348–1353.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).Blood. 2000;95:1931–1934.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Gluckman E, Rokicka-Milewska R, Gordon-Smith EC, et al. Results of a randomized study of glycosylated rHuG-CSF Lenogastrim in severe aplastic anemia [abstract].Blood 998; 92(suppl 1):376a.Google Scholar
  54. 54.
    Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.Blood. 2000;96:2049–2054.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Matloub YH, Smith C, Bostrom B, et al. One course versus two courses of antithymocyte globulin for the treatment of severe aplastic anemia in children.J Pediatr Hematol Oncol. 1997;19:110–114.PubMedGoogle Scholar
  56. 56.
    Fuhrer M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience.Klin Padiatr. 1998;210:173–179.PubMedGoogle Scholar
  57. 57.
    Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. The European Group for Blood and Marrow Transplantation Several Aplastic Anaemia Working Party.Ann Intern Med. 1999;130:193–201.PubMedGoogle Scholar
  58. 58.
    Marmont AM, Bacigalupo A, van Lint MT, et al. Treatment of severe aplastic anemia with sequential immunosuppression.Exp Hematol. 1983;11:856–865.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplas-tic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party.Br J Haematol. 1993;85:371–377.PubMedGoogle Scholar
  60. 60.
    Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy.Br J Haematol. 1999;107:330–334.PubMedGoogle Scholar
  61. 61.
    Crump M, Larratt LM, Maki E, et al. Treatment of adults with severe aplastic anemia: primary therapy with antithymocyte globulin (ATG) and rescue of ATG failures with bone marrow transplantation.Am J Med. 1992;92:596–602.PubMedGoogle Scholar
  62. 62.
    Lawlor ER, Anderson RA, Davis JH, et al. Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?J Pediatr Hematol Oncol. 1997;19:115–123.PubMedGoogle Scholar
  63. 63.
    Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.Semin Hematol. 2000;37:43–55.PubMedGoogle Scholar
  64. 64.
    Vassiliou GS, Webb DKH, Pamphilon D, Knapper S, Veys PA. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath.Br J Haematol. 2001;114:701–705.PubMedGoogle Scholar
  65. 65.
    Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation.Br J Haematol. 2001;114:706–711.PubMedGoogle Scholar
  66. 66.
    Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy.Biol Blood Marrow Transplant. 1999;5:243–252.PubMedGoogle Scholar
  67. 67.
    Grima KM. Therapeutic apheresis in hematological and oncological diseases.J Clin Apheresis. 2000;15:28–52.PubMedGoogle Scholar
  68. 68.
    Ito T, Hiraiwa M, Ishikawa Y, et al. Lymphocytapheresis in a patient with severe aplastic anemia.Acta Haematol. 1988;80:167–170.PubMedGoogle Scholar
  69. 69.
    Morales-Polanco MR, Sanchez-Valle E, Guerrero-Rivera S, Gutierrez-Alamillo L, Delgado-Marquez B. Treatment results of 23 cases of severe aplastic anemia with lymphocytapheresis.Arch Med Res. 1997;28:85–90.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Young NS, Klein HG, Griffith P, Nienhuis AW. A trial of immunotherapy in aplastic anemia and pure red cell aplasia.J Clin Apheresis. 1983;1:95–103.PubMedGoogle Scholar
  71. 71.
    Bacigalupo A, Podesta’ M, van Lint MT, et al. Severe aplastic anaemia: correlation of in vitro tests with clinical response to immunosuppression in 20 patients.Br J Haematol. 1981;47:423–433.PubMedGoogle Scholar
  72. 72.
    Doney K, Pepe M, Storb R, et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxy metholone to ATG, very high-dose methylprednisolone, and oxymetholone.Blood. 1992;79:2566–2571.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Schwinger W, Urban C, Lackner H, Mache C. Treatment of aplastic anemia with a monoclonal antibody directed against the interleukin-2 receptor.Ann Hematol. 1993;66:181–184.PubMedGoogle Scholar
  74. 74.
    Jansen J, Gratama JW, Zwaan FE, Simonis RFA. Therapy with monoclonal antibody OKT3 in severe aplastic anemia.Exp Hematol. 1984;12(suppl 15):46–47.Google Scholar
  75. 75.
    Doney K, Martin P, Storb R, et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia.Exp Hematol. 1985;13:520–524.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.Br J Haematol. 2001;114:891–898.PubMedGoogle Scholar
  77. 77.
    Thomas ED, Storb R, Giblett ER, et al. Recovery from aplastic anemia following attempted marrow transplantation.Exp Hematol. 1976;4:97–102.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Territo MC. Autologous bone marrow repopulation following high dose cyclophosphamide and allogeneic marrow transplantation in aplastic anemia.Br J Haematol. 1977;36:305–311.PubMedGoogle Scholar
  79. 79.
    Tisdale JF, Dunn DE, Maciejewski J. Cyclophosphamide and other new agents for the treatment of severe aplastic anemia.Semin Hematol. 2000;37:102–109.PubMedGoogle Scholar
  80. 80.
    Baran DT, Griner PF, Klemperer MR. Recovery from aplastic anemia after treatment with cyclophosphamide.N Engl J Med. 1976;295:1522–1523.PubMedGoogle Scholar
  81. 81.
    Griner PF. A survey of the effectiveness of cyclophosphamide in patients with severe aplastic anemia.Am J Hematol. 1980;8:55–60.PubMedGoogle Scholar
  82. 82.
    Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation.Blood. 1996;87:491–494.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high dose cyclophosphamide therapy for previously severe aplastic anemia.Ann Intern Med. 2001;135:477–483.PubMedGoogle Scholar
  84. 84.
    Tisdale JF, Dunn DE, Geller NL, et al. High-dose cyclophosphamide in severe aplastic anemia: a randomized trial.Lancet. 2000;356:1554–1559.PubMedGoogle Scholar
  85. 85.
    Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. Highdose cyclophosphamide in the treatment of severe aplastic anemia in children.Ann Hematol. 2001;66:71.Google Scholar
  86. 86.
    Li Z, Yin S, Xie S, Ma L, Nie D, Xsu L. Treatment of severe aplastic anemia using high-dose cyclophosphamide in China.Haematologica. 2000;85:1–2.Google Scholar
  87. 87.
    Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS. A randomized trial comparing antithymocyte globulin and cyclosporin to cyclophosphamide and cyclosporin for initial treatment in severe aplastic anemia: results of long-term follow-up [abstract].Blood. 2001;98(Part 1):223a.Google Scholar
  88. 88.
    Heimpel H. Aplastic anemia before bone marrow transplantation and antilymphocyte globulin.Acta Haematol. 2000;103:11–15.PubMedGoogle Scholar
  89. 89.
    Maciejewski JP, Rivera C, Dunn D, Young NS. Clinical features of the relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria.Br J Haematol. 2001;115:1015–1021.PubMedGoogle Scholar
  90. 90.
    Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia.Semin Hematol. 2000;37:91–101.PubMedGoogle Scholar
  91. 91.
    Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia.N Engl J Med. 1993;329:1152–1157.PubMedGoogle Scholar
  92. 92.
    Maciejewski JP, Risitano AM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.Blood. In press.Google Scholar
  93. 93.
    Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia.Haematologica. 1996;81:418–422.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Arranz R, Otero MJ, Ramos R, et al. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy.Bone Marrow Transplant. 1994;13:383–387.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation.Blood. 1995;85:283–290.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Gillio AP, Boulad F, Small TN, et al. Comparison of long-term outcome of children with severe aplastic anemia treated with immuno-suppression versus bone marrow transplantation.Biol Blood Marrow Transplant. 1997;5:18–24.Google Scholar
  97. 97.
    Fouladi M, Herman R, Roland-Grinton M, et al. Improved survival in severe acquired aplastic anemia of childhood.Bone Marrow Transplant. 2000;26:1149–1156.PubMedGoogle Scholar
  98. 98.
    Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-the European Group for Blood and Marrow Transplantation experience.Semin Hematol. 2000;37:69–80.PubMedGoogle Scholar
  99. 99.
    Fisch P. Pure red cell aplasia.Br J Haematol. 2000;111:1010–1022.PubMedGoogle Scholar
  100. 100.
    Abkowitz JL. Acquired pure red cell aplasia: physiology and therapy. In: Schechter GP, Berliner N, Telen MJ, eds.Hematology 2000. Washington, DC: American Socity of Hematology; 2000:24–27.Google Scholar
  101. 101.
    Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities.Blood. 1996;87:3000–3006.PubMedPubMedCentralGoogle Scholar
  102. 102.
    Handgretinger R, Geiselhart A, Moris A. Pure red cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors.N Engl J Med. 2001;340:278–284.Google Scholar
  103. 103.
    Go RS, Li C-Y, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes.Blood. 2001;98:483–485.PubMedGoogle Scholar
  104. 104.
    Yamada O, Mizoguchi H, Oshimi K. Cyclophosphamide therapy for pure red cell aplasia associated with granular lymphocyte-proliferative disorders.Br J Haematol. 1997;97:392–399.PubMedGoogle Scholar
  105. 105.
    Yamada O, Motoji T, Mizoguchi H. Selective effect of cyclosporine monotherapy for pure red cell aplasia not associated with granular lymphocyte-proliferative disorders.Br J Haematol. 1999;106:371–376.PubMedGoogle Scholar
  106. 106.
    Coutinho J, Lima M, dos AnjosTeixeira M, Cabeda JM, Leite F, Justica B. Pure red cell aplasia associated to clonal CD8+ T cell large granular lymphocytosis: dependence on cyclosporin A therapy.Acta Haematol. 1998;100:207–210.PubMedGoogle Scholar
  107. 107.
    Yamada O. Clonal T cell proliferation in patients with pure red cellaplasia.Leuk Lymphoma. 1999;35:69–82.PubMedGoogle Scholar
  108. 108.
    Abkowitz JL, Powell JS, Nakamura JM, Kadin ME, Adamson JW. Pure red cell aplasia: response to therapy with anti-thymocyte globulin.Am J Hematol. 1986;23:363–371.PubMedGoogle Scholar
  109. 109.
    Mangan KF, Shadduck RK. Successful treatment of chronic refractory pure red cell aplasia with antithymocyte globulin: correlation with in vitro erythroid culture studies.Am J Hematol. 1984;17:417–426.PubMedGoogle Scholar
  110. 110.
    Kwong YL, Wong KF. Association of pure red cell aplasia with T large granular lymphocyte leukaemia.J Clin Pathol. 1998;54:672–675.Google Scholar
  111. 111.
    Ustun C, Karaveliogiu D, Ilhan O, Aydintug O, Beksac M. A case report of a patient who has pure red cell aplasia and rheumatoid arthritis.Int J Hematol. 1997;66:505–512.PubMedGoogle Scholar
  112. 112.
    Ueda K, Matsubara A, Kizuki N, Sato Y, Oka Y. Successful treatment of acquired pure red cell aplasia and acquired amegakaryocytic thrombocytopenia with anti-thymocyte globulin.Ann J Hematol. 2001;66:154–155.Google Scholar
  113. 113.
    Ahn JH, Lee KH, Lee JH, et al. A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment.Br J Haematol. 2001;112:527–529.PubMedGoogle Scholar
  114. 114.
    Manoharan A, Williams NT, Sparrow R. Acquired amegakary-ocytic thrombocytopenia: report of a case and review of literature.Q J Med. 1989;70:243–252.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Rosenfeld S. Amegakaryocytic thrombocytopenia. In: Young NS, ed.The Bone Marrow Transplantation Syndromes. Philadelphia, Pa: W. B. Saunders; 2000:183–186.Google Scholar
  116. 116.
    Trimble MS, Glynn MF, Brain MC. Amegakaryocytic thrombocytopenia of 4 years duration: success treatment with antithymocyte globulin.Am J Hematol. 1991;37:126–127.PubMedGoogle Scholar
  117. 117.
    Spath-Schwalbe E, Arnold R, Flath B, Possinger K. Red cell aplasia and megakaryocytic hypoplasia with elevated counts of CD8-positive lymphocytes after resection of a thymoma responding to cyclosporine.Ann Hematol. 1998;76:51–52.PubMedGoogle Scholar
  118. 118.
    Leach J, Hussein KK, George JN. Acquired pure megakaryocytic aplasia report of two cases with long-term responses to antithymocyte globulin and cyclosporine.Am J Hematol. 1999;62:115–117.PubMedGoogle Scholar
  119. 119.
    Litzow MR, Kyle RA. Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome.Am J Hematol. 1989;32:226–229.Google Scholar
  120. 120.
    Young NS, Barrett AJ. Immune modulation of myelodysplasia: rationale and therapy. In: Bennett JM, ed.The Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York:Marcel Dekker; in press, 2002.Google Scholar
  121. 121.
    Hamblin T. Immunologic abnormalities in myelodysplastic syndromes.Hematol Oncol Clin North Am. 1992;6:571–586.PubMedGoogle Scholar
  122. 122.
    Saunthararajah Y, Molldrem JJ, Rivera M, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features.Br J Haematol. 2001;112:195–200.PubMedGoogle Scholar
  123. 123.
    Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin for myelodysplastic syndrome?Br J Haematol. 1988;68:139–140.PubMedGoogle Scholar
  124. 124.
    Miescher PA, Favre H, Beris P. Autoimmune myelodysplasias.Semin Hematol. 1991;28:322–329.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome.Cancer. 1997;79:1548–1551.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Molldrem nJ, Rivera M, Bahceci E, et al. Treatment of bone marrow failure of myelodysplastic syndrome with antithymocyte globulin.Ann Intern Med. In press.Google Scholar
  127. 127.
    Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.Br J Haematol. 1998;200:304–309.Google Scholar
  128. 128.
    Shimamoto T, Iguchi T, Ando K, et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements.Br J Haematol. 2001;114:358–361.PubMedGoogle Scholar
  129. 129.
    Tamayose K, Sugimoto K, Ando M, Oshimi K. Disappearance of chromosomal abnormalities and recovery of hematopoiesis after immunosuppressive therapy for hypoplastic refractory anemia with excess of blasts.Blood. 2001;97:2524.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  1. 1.Hematology Branch, National Heart, Lung, and Blood Institute, NIHBethesda, MarylandUSA

Personalised recommendations